BioXcel Therapeutics, Inc. Accrued Liabilities, Current
BioXcel Therapeutics, Inc. (BTAI) had Accrued Liabilities, Current of $3.92 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-13
- 2026-06-30: Accrued Liabilities, Current $3.92M.
- 2026-03-31: Accrued Liabilities, Current $6.39M.
- 2025-12-31: Accrued Liabilities, Current $4.34M.
- 2025-09-30: Accrued Liabilities, Current $4.36M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $3.92M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $6.39M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $4.34M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $4.36M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $5.09M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $3.99M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $5.76M 10-K · filed 2026-03-27 |
| 2024-09-30 | $10.19M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $13.48M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $13.68M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $12.42M 10-K · filed 2025-03-28 |
| 2023-09-30 | $26.61M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $19.13M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $17.07M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $18.67M 10-K · filed 2024-03-22 |
| 2022-09-30 | $13.95M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $13.37M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $10.58M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $11.49M 10-K · filed 2023-03-16 |
| 2021-09-30 | $10.72M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $9.56M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $6.53M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $7.47M 10-K · filed 2022-03-11 |
| 2020-09-30 | $6.90M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $4.53M 10-Q · filed 2020-08-14 |
| 2020-03-31 | $3.60M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $3.12M 10-K · filed 2021-03-12 |
| 2019-09-30 | $3.39M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $3.37M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $3.35M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $3.06M 10-K · filed 2020-03-09 |
| 2018-09-30 | $830.00K 10-Q · filed 2018-11-09 |
| 2018-06-30 | $500.00K 10-Q · filed 2018-08-08 |
| 2018-03-31 | $267.00K 10-Q · filed 2018-05-14 |
| 2017-12-31 | $1.01M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |